DEBRA RAPPAZZO: Open Payments
NPI 1508067182 · LATHAM, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$492 in 23 payments from 12 companies in 2025. Trend: 2023 $894 · 2024 $947 · 2025 $492
Food & beverage: $492
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $108 |
| Exeltis, USA Inc. | 3 | $64 |
| Astellas Pharma US Inc | 3 | $59 |
| ABBVIE INC. | 3 | $55 |
| MILLICENT US INC | 2 | $38 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| SHIELD THERAPEUTICS INC | 2 | $31 |
| Exact Sciences Corporation | 1 | $27 |
| PFIZER INC. | 1 | $20 |
| Organon LLC | 1 | $18 |
Products named: Wegovy, SLYND, Veozah, LILETTA, FEMLYV, ACCRUFER, The Cologuard Plus Collection Kit, MYFEMBREE.
Industry payments across NY — which companies pay providers there.
